Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis
NCT ID: NCT01812954
Last Updated: 2017-08-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1 participants
OBSERVATIONAL
2013-03-31
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study aims to investigate the comparative cost-effectiveness of biologic and conventional systemic treatments currently (as of June 1st, 2012) approved for moderate-to-severe plaque-type psoriasis in Germany. Effectiveness will be measured by means of the pooled (Psoriasis Area and Severity Index) PASI-75 response rates as reported in RCTs Direct cost as well as indirect cost will be considered.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation
NCT02330380
Swiss Dermatology Network of Targeted Therapies (SDNTT)
NCT01706692
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)
NCT01729754
Regulatory T-cells in Psoriasis Patients as Targets for Therapy
NCT01233583
Psoriasis Longitudinal Assessment and Registry
NCT00508547
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Methotrexate
Cyclosporins
fumaric acid
Acitretin
Infliximab
etanercept
Adalimumab
Ustekinumab
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
16 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Jochen Schmitt.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jochen Schmitt.
Director of Center for evidence-based healthcare
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jochen Schmitt, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
University Dresden
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
50310
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
PSO-GOE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.